CN110101719A - 一种新型皮肤消毒剂 - Google Patents
一种新型皮肤消毒剂 Download PDFInfo
- Publication number
- CN110101719A CN110101719A CN201810099476.3A CN201810099476A CN110101719A CN 110101719 A CN110101719 A CN 110101719A CN 201810099476 A CN201810099476 A CN 201810099476A CN 110101719 A CN110101719 A CN 110101719A
- Authority
- CN
- China
- Prior art keywords
- skin
- alprostadil
- aspirin
- lysine
- disinfectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000645 desinfectant Substances 0.000 title claims description 19
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000711 alprostadil Drugs 0.000 claims abstract description 18
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract description 18
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- -1 lysine compound Chemical class 0.000 claims abstract description 9
- 239000004472 Lysine Substances 0.000 claims abstract description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 6
- 244000000010 microbial pathogen Species 0.000 claims abstract description 6
- 238000004140 cleaning Methods 0.000 claims abstract 2
- 210000003491 skin Anatomy 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 238000004090 dissolution Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 8
- 229940033663 thimerosal Drugs 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000036770 blood supply Effects 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 210000003899 penis Anatomy 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000008326 skin blood flow Effects 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- KZDMWVBUOTWRDX-UHFFFAOYSA-J sodium cerium(3+) tetrahydroxide Chemical compound [OH-].[Na+].[Ce+3].[OH-].[OH-].[OH-] KZDMWVBUOTWRDX-UHFFFAOYSA-J 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 230000009946 DNA mutation Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 abstract description 4
- 239000003206 sterilizing agent Substances 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 2
- 230000002262 irrigation Effects 0.000 abstract 1
- 238000003973 irrigation Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Animal Husbandry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明涉及一种前列地尔和阿司匹林或其赖氨酸复方新型消毒剂配方、制备工艺、用途。可作为皮肤清洗和消毒两用。现有皮肤消毒剂原理是直接杀灭、抑制皮肤上病原微生物,这样对皮肤也有损伤作用。为了克服现有皮肤消毒剂缺陷,本发明提供一种前列地尔和阿司匹林或其赖氨酸盐复方新型消毒剂配方、配制工艺、使用方法、用途。对皮肤具有清洗、消毒、保护、滋润作用。
Description
技术领域
本发明涉及一种前列地尓和阿司匹林或其赖氨酸盐复方新型消毒剂配方、制备工艺、使用方法、用途。
技术背景
现有皮肤消毒剂原理是直接杀灭、抑制皮肤上病原微生物,这样对皮肤也有损伤作用。
发明内容
为了克服现有皮肤消毒剂缺陷,本发明提供一种前列地尓和阿司匹林或其赖氨酸盐复方新型消毒剂配方、配制工艺、使用方法、用途。
其原料配方的重量比是:
制备工艺及使用方法:
1、把蜂蜜、2-羟丙基-β-环糊精在80-100转/分钟速度搅拌下,分别加入0.9%氯化钠溶液中,分别溶解完全。
2、把第一步制的溶液在121度温度下灭菌15分钟,在温度60度至65度时,用0.22μm滤过。
3、滤过后溶液冷却到室温,在80-100转/分钟速度搅拌下,加入阿司匹林或其赖氨酸盐,溶解完全。
4、把前列地尔在80-120转/分钟搅拌下,加入无水乙醇中,至溶解完全。
5、把第四步制的前列地尔无水乙醇溶液,在80-100转/分钟速度搅拌下,滴加方式加入第3步制的0.9%氯化钠溶液中,2-羟丙基-β-环糊精把在水中从稀释了的乙醇中析出前列地尔包裹,使前列地尔溶解完全。
6、用重量百分比8%分析纯氢氧化钠溶液调pH值8.5,用0.22μm滤过。
7、再用重量百分比8%分析纯柠檬酸溶液调pH值6.5-7.5。
8、在B级无菌条件下,灌装,规格有:10ml、20ml、30ml、50ml、60ml、80ml、100ml、200ml、300ml、500ml规格的喷雾剂。
9、喷洒在所要消毒的皮肤部位,每天早上、中午、晚上洗净皮肤后喷洒,或早、晚洗净皮肤喷洒;也可以用此消毒剂喷洒,洗净消毒皮肤处。下次消毒时,可用此消毒剂作为清洗液,清洗前次残留物,再作消毒液。
本发明的发明优势:
1、本发明在传统的消毒剂乙醇、0.9%氯化钠、蜂蜜对皮肤消毒基础上,使用了抗血栓、抗血板聚集、扩张血管、改善微循环前列地尓,改善消毒皮肤局部血液流通,血液供应消毒位皮肤营养,增强抑制消毒部位病原微生物免疫力,血液滋润皮肤。
2、阿司匹林赖氨酸盐渗入皮肤中会分解成阿司匹林和赖氨酸,阿司匹林有保护皮肤细胞DNA不产生突变作用,抗血小板聚集、抗血栓、止痛作用,可以改善消毒皮肤处活血化瘀,加速皮肤恢复正常,赖氨酸是人体不可合成的又是人体必须氨基酸,供给皮肤营养,滋润皮肤。
3、2-羟丙基-β-环糊精把在水中从稀释了的乙醇中析出前列地尔包裹,在前列地尓被皮肤吸收后,2-羟丙基-β-环糊精和被包裹残存前列地尓、蜂蜜在皮肤消毒处形成皮肤软薄层保护膜,消毒处皮肤与空气中病原微生物隔离,不会再感染。
4、蜂蜜使消毒液粘在消毒皮肤部位,不会流走,并有丰富营养,滋润消毒处皮肤。
5、用于脸部、阴道、阴茎、伤口、全身皮肤消毒。下次消毒时,可用此消毒剂作为清洗液,清洗前次残留物,再作消毒液。消毒、清洗两用。
具体实施方式
实施例1
其原料配方的重量比是:
制备工艺、使用方法:同前面所述。
实施例2
其原料配方的重量比是:
制备工艺、使用方法:同前面所述。
实施例3
其原料配方的重量比是:
制备工艺、使用方法:同前面所述。
实施例4
其原料配方的重量比是:
制备工艺、使用方法:同前面所述。
实施例5
其原料配方的重量比是:
制备工艺、使用方法:
同前面所述。
消毒效果验证:
穆良芹等30人,15人用实施例1消毒剂,于脸上早中晚红痘痘喷洒10天,15人用对照消毒液为75%药用乙醇;
谭小梅等30人,15人用实施例2消毒剂,于夏天被毒虫咬红包上早中晚喷洒10天,15人用对照消毒液0.9%氯化钠注射液;
白xx等30人,15人用实施例3消毒剂,每天晚上向子宫颈炎处喷洒,对照液为0.9%氯化钠注射液;
陈青兰等30人,15人用实施例4消毒液喷洒脚气皮肤,每天晚上洗脚后喷洒一次,15人用对照消毒液为0.9%氯化钠液;
唐xx等30人,15人用实施例5消毒剂喷洒糖尿病神经皮炎,15人用对照液75%乙醇,每天早中晚喷洒3次。
效果如下表:
可见本发明消毒剂优越。
Claims (5)
1.一种前列地尔和阿司匹林或其赖氨酸盐复方消毒剂,其特征是,其原料重量比和制备方法是:
其原料配方的重量比是:
制备工艺及使用方法:
(1)把蜂蜜、2-羟丙基-β-环糊精在80-100转/分钟速度搅拌下,分别加入0.9%氯化钠溶液中,分别溶解完全。
(2)把第一步制的溶液在121度温度下灭菌15分钟,在温度60度至65度时,用0.22μm滤过。
(3)滤过后溶液冷却到室温,在80-100转/分钟速度搅拌下,加入阿司匹林或其赖氨酸盐,溶解完全。
(4)把前列地尔在80-120转/分钟搅拌下,加入无水乙醇中,至溶解完全。
(5)把第四步制的前列地尔无水乙醇溶液,在80-100转/分钟速度搅拌下,滴加方式加入第3步制的0.9%氯化钠溶液中,2-羟丙基-β-环糊精把在水中从稀释了的乙醇中析出前列地尔包裹,使前列地尔溶解完全。
(6)用重量百分比8%分析纯氢氧化钠溶液调pH值8.5,用0.22μm滤过。
(7)再用重量百分比8%分析纯柠檬酸溶液调pH值6.5-7.5。
(8)在B级无菌条件下,灌装,规格有:10ml、20ml、30ml、50ml、60ml、80ml、100ml、200ml、300ml、500ml规格的喷雾剂。
(9)喷洒在所要消毒的皮肤部位,每天早上、中午、晚上洗净皮肤后喷洒,或早、晚洗净皮肤喷洒;也可以用此消毒剂喷洒,洗净消毒皮肤处。下次消毒时,可用此消毒剂作为清洗液,清洗前次残留物,再作消毒液。
2.依权利要求1所述,一种前列地尔和阿司匹林或其赖氨酸盐复方消毒剂,其特征是,本发明在传统的消毒剂乙醇、0.9%氯化钠、蜂蜜对皮肤消毒基础上,使用了改善微循环前列地尔和抑制血小板聚集的阿司匹林或其赖氨酸盐,改善消毒皮肤局部血液流通,血液供应消毒位皮肤营养,消除、抑制消毒部位病原微生物,滋润皮肤。
3.依权利要求1所述,一种前列地尔和阿司匹林或其赖氨酸盐复方消毒剂,其特征是,阿司匹林赖氨酸盐渗入皮肤中会分解成阿司匹林和赖氨酸,阿司匹林有保护皮肤细胞DNA不产生突变作用,赖氨酸是人体不可合成的又是人体必须氨基酸供给皮肤营养。
4.依权利要求1所述,一种前列地尔和阿司匹林或其赖氨酸盐复方消毒剂,其特征是,2-羟丙基-β-环糊精把在水中从稀释了的乙醇中析出前列地尔包裹,在前列地尔被皮肤吸收后,2-羟丙基-β-环糊精和被包裹残存前列地尔、蜂蜜在皮肤消毒处形成皮肤软保护膜,消毒处皮肤与空气中病原微生物隔离,不会再感染。
5.依权利要求1所述,一种前列地尔和阿司匹林或其赖氨酸盐复方消毒剂,其特征是,用于脸部、阴道、阴茎、伤口、全身皮肤消毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810099476.3A CN110101719A (zh) | 2018-02-01 | 2018-02-01 | 一种新型皮肤消毒剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810099476.3A CN110101719A (zh) | 2018-02-01 | 2018-02-01 | 一种新型皮肤消毒剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110101719A true CN110101719A (zh) | 2019-08-09 |
Family
ID=67483559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810099476.3A Pending CN110101719A (zh) | 2018-02-01 | 2018-02-01 | 一种新型皮肤消毒剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110101719A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001089363A (ja) * | 1999-09-24 | 2001-04-03 | Ataru Kida | キレート剤を添加したエタノール消毒剤 |
CN1915222B (zh) * | 2006-09-18 | 2010-08-04 | 蔡海德 | 一种脂质体组合物及其制备方法 |
CN105816339A (zh) * | 2016-04-21 | 2016-08-03 | 江苏鱼跃信息系统有限公司 | 一种免洗手消毒液及其制备方法 |
-
2018
- 2018-02-01 CN CN201810099476.3A patent/CN110101719A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001089363A (ja) * | 1999-09-24 | 2001-04-03 | Ataru Kida | キレート剤を添加したエタノール消毒剤 |
CN1915222B (zh) * | 2006-09-18 | 2010-08-04 | 蔡海德 | 一种脂质体组合物及其制备方法 |
CN105816339A (zh) * | 2016-04-21 | 2016-08-03 | 江苏鱼跃信息系统有限公司 | 一种免洗手消毒液及其制备方法 |
Non-Patent Citations (3)
Title |
---|
SUE-LANG HUANG 等: "Survival of Staphylococcus aureus and Escherichia coli as Affected by Ethanol and NaCl", 《JOURNAL OF FOOD PROTECTION》 * |
李青: "生理盐水替代酒精皮试消毒的效果观察", 《华北煤炭医学院学报》 * |
陈声宗 等编: "《化工研究进展》", 30 September 1996 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4668513A (en) | Method for combating snoring | |
RU2007143998A (ru) | Мукоадгезивные ксилоглюкансодержащие препараты, полезные в медицинских устройствах и в фармацевтических препаратах | |
NO331654B1 (no) | Xylitolblandinger, farmasoytisk preparat, nesespray og medisinert vattpinne. | |
US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
CN114224771B (zh) | 一种免洗洗手液及其制备方法 | |
CN107519081A (zh) | 一种具有祛痘修复功效的组合物及制备方法 | |
AU2004287281A1 (en) | Disinfecting composition and methods of making and using same | |
CN109394837A (zh) | 一种鼻腔喷雾剂及其制备方法 | |
CN107184427A (zh) | 一种含聚谷氨酸和透明质酸的协同组合物及应用 | |
AU2021200611A1 (en) | Compositions and methods of use | |
CN103007278A (zh) | 一种抗牙龈卟啉单胞菌和具核梭杆菌复合特异性IgY抗体及其制备方法和牙膏 | |
CN105640835A (zh) | 一种祛痘用组合物及其应用 | |
CN107899006A (zh) | 冲洗鼻腔的药物组合物及其制备方法 | |
CN102861206A (zh) | 皮肤粘膜杀菌消毒气雾剂及其制备方法 | |
CN101278908B (zh) | 一种左氧氟沙星滴眼液 | |
CN110101719A (zh) | 一种新型皮肤消毒剂 | |
CN105412913B (zh) | 一种鼻腔润湿剂 | |
CN105381454B (zh) | 一种含海藻糖的鼻腔润湿剂 | |
CN107281001A (zh) | 一种含透明质酸的活性调理喷雾及其制备方法 | |
CN111388421A (zh) | 一种具有抗菌和抗病毒功能的口鼻喉双组分喷剂及制备方法 | |
CN110721189A (zh) | 一种皮肤消毒剂 | |
CN110507727A (zh) | 一种治疗鼻炎的喷雾制剂及其制备方法 | |
CN103191159B (zh) | 一种消炎抑菌制剂及其制备方法和应用 | |
CN109464328A (zh) | 植物型抑菌止痒液 | |
CN101283956A (zh) | 胆碱酯酶在治疗或改善皮肤症状的皮肤护理用品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190809 |